Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.

Eur J Nucl Med Mol Imaging · 2019 · PMC6717604 · PMID 31367906

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

borderline significancep = 0.053so close (0.05 < p ≤ 0.1)

In the retrospective cohort, age and ECOG PS were significant prognostic factors ( p = 0.039 and 0.024, respectively), and T stage demonstrated borderline significance ( p = 0.053).

also in 7,017 other papers

a positive trendno p-value reported

Preliminary results demonstrated a positive trend in a cohort comparison towards improved OS and PFS in the prospective cohort, suggesting a benefit from implementing FDG PET/CT-guided concurrent CRT in patients with stage III NSCLC in centres in LMIC with limited experience with PET/CT.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.